Elutia Inc. reported its financial results for the second quarter of 2025, revealing a net loss of $9.6 million, a significant improvement compared to a net loss of $28.4 million in the same period last year. The company's total revenue for the quarter was $6.3 million, nearly unchanged from $6.3 million in the prior year. The gross profit increased to $3.1 million, up from $2.8 million, reflecting a gross margin of 48.8%, compared to 44.5% in the previous year. The improvement in gross margin was attributed to enhanced production efficiencies in the Device Protection segment, particularly with the EluPro product, which had its full commercial launch in January 2025 following FDA clearance in June 2024.
In terms of operational metrics, Elutia's Device Protection segment saw a revenue increase of 33.2% year-over-year, driven by the successful launch of EluPro. However, the Women's Health and Cardiovascular segments experienced declines, with Women's Health revenues decreasing due to a shift of physician users to hospitals where the product is not yet available, and Cardiovascular sales dropping following the termination of an exclusive distribution agreement with LeMaitre Vascular. The company anticipates a rebound in Cardiovascular sales as it resumes direct sales through independent agents.
Elutia's total operating expenses for the quarter rose to $12.9 million, up from $11.3 million, primarily due to increased litigation costs related to ongoing legal matters, which amounted to $4.0 million compared to $2.3 million in the previous year. General and administrative expenses decreased significantly, reflecting cost management efforts. The company reported a cash balance of $8.5 million as of June 30, 2025, down from $13.2 million at the end of 2024, largely due to cash used in operating activities.
Strategically, Elutia completed the sale of its Orthobiologics Business in November 2023 for $14.6 million, with potential additional earn-out payments of up to $20 million based on future sales. This divestiture has allowed the company to focus on its core products in Device Protection and Women's Health. The company is also expanding its manufacturing capabilities with a new facility in Gaithersburg, Maryland, which is expected to enhance production efficiency for its product lines.
Looking ahead, Elutia faces challenges in achieving profitability, with an accumulated deficit of $243.1 million as of June 30, 2025. The company plans to continue investing in the commercialization of EluPro and expanding its product offerings. However, there is substantial doubt about its ability to continue as a going concern within the next year, prompting the need for potential capital raises through equity or debt financing. The company remains focused on navigating its operational and financial challenges while pursuing growth opportunities in its targeted markets.
About ELUTIA INC.
Elutia Inc. develops regenerative medicine products focused on device protection, women's health, and cardiovascular repair. Its offerings include bioenvelopes with antimicrobial properties and acellular dermal matrices to reduce complications like infection, migration, and fibrosis. The company leverages proprietary tissue engineering, strategic partnerships, and a scalable manufacturing model to serve healthcare providers, aiming to improve surgical outcomes and establish standards in implantable device and tissue reconstruction markets.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.